What is SFC Fluidics?
SFC Fluidics, Inc. is at the forefront of developing advanced devices designed to revolutionize diabetes management. Their flagship innovation, the proprietary Panda Insulin Delivery System, directly addresses the substantial global healthcare burden of diabetes, which consumes approximately 10% of worldwide healthcare expenditures. By focusing on enhancing clinical efficacy and reducing treatment expenses, SFC Fluidics aims to make a significant impact on patient lives. As a participant in the VIC Technology Venture Development ecosystem, the company is strategically positioned to broaden its technological applications beyond diabetes to other critical disease areas, leveraging its expertise in medical device innovation.
How much funding has SFC Fluidics raised?
SFC Fluidics has raised a total of $3.6M across 5 funding rounds:
Private Equity
$1M
Series B
$2M
Unspecified
$175K
Debt
$144K
Private Equity
$250K
Private Equity (2013): $1M, investors not publicly disclosed
Series B (2014): $2M, investors not publicly disclosed
Unspecified (2015): $175K supported by National Institutes of Health
Debt (2021): $144K featuring PPP
Private Equity (2025): $250K, investors not publicly disclosed
Key Investors in SFC Fluidics
National Institutes of Health
The National Institutes of Health (NIH) is a leading U.S. government agency dedicated to biomedical and health-related research, playing a crucial role in advancing medical science and public health initiatives.
What's next for SFC Fluidics?
The recent major strategic investment signals a pivotal growth phase for SFC Fluidics. With substantial enterprise-level backing, the company is poised to accelerate the development and commercialization of its next-generation diabetes care devices, including the Panda Insulin Delivery System. This capital infusion will likely fuel expansion into new markets, further research and development for additional disease states, and the scaling of manufacturing capabilities. SFC Fluidics' trajectory suggests a move towards broader market penetration and potentially strategic partnerships to amplify its reach and impact in the global healthcare landscape.
See full SFC Fluidics company page
